Both lysophosphatidic acid (LPA) and antidepressants have been shown to affect neuronal survival and differentiation, but whether LPA signalling participates in the action of antidepressants is still unknown. In this study, we examined the role of LPA receptors in the regulation of extracellular signal-regulated protein kinases 1 and 2 (ERK1/2) activity and neuronal survival by the tetracyclic antidepressants, mianserin and mirtazapine in hippocampal neurons. In HT22 immortalized hippocampal cells, antidepressants and LPA induced a time- and concentration-dependent stimulation of ERK1/2 phosphorylation. This response was inhibited by either LPA1 and LPA1/3 selective antagonists or siRNA-induced LPA1 down-regulation, and enhanced by LPA1 over-expression. Conversely, the selective LPA2 antagonist H2L5186303 had no effect. Antidepressants induced cyclic AMP response element binding protein phosphorylation and this response was prevented by LPA1 blockade. ERK1/2 stimulation involved pertussis toxin-sensitive G proteins, Src tyrosine kinases and fibroblast growth factor receptor (FGF-R) activity. Tyrosine phosphorylation of FGF-R was enhanced by antidepressants through LPA1 . Serum withdrawal induced apoptotic death, as indicated by increased annexin V staining, caspase activation and cleavage of poly-ADP-ribose polymerase. Antidepressants inhibited the apoptotic cascade and this protective effect was curtailed by blockade of either LPA1 , ERK1/2 or FGF-R activity. Moreover, in primary mouse hippocampal neurons, mianserin acting through LPA1 increased phospho-ERK1/2 and protected from apoptosis induced by removal of growth supplement. These data indicate that in neurons endogenously expressed LPA1 receptors mediate intracellular signalling and neuroprotection by tetracyclic antidepressants.
Pubmed ID: 28815598 RIS Download
Publication data is provided by the National Library of Medicine ® and PubMed ®. Data is retrieved from PubMed ® on a weekly schedule. For terms and conditions see the National Library of Medicine Terms and Conditions.
This monoclonal targets FGF-2 / basic FGF
View all literature mentionsThis polyclonal targets Mapk3
View all literature mentionsThis monoclonal targets beta-3-Tubulin
View all literature mentionsThis monoclonal targets EDG-2
View all literature mentionsThis monoclonal targets Casp3
View all literature mentionsThis polyclonal targets phospho-CREB (Ser133)
View all literature mentionsThis polyclonal targets Glial Fibrillary Acidic Protein
View all literature mentionsThis monoclonal targets Neurofilament 160/200 antibody produced in mouse
View all literature mentionsThis monoclonal targets EDG-2
View all literature mentionsThis monoclonal targets beta-3-Tubulin
View all literature mentionsThis polyclonal targets Mapk3
View all literature mentionsThis monoclonal targets FGF-2 / basic FGF
View all literature mentionsThis monoclonal targets Casp3
View all literature mentionsThis polyclonal targets phospho-CREB (Ser133)
View all literature mentionsThis polyclonal targets Glial Fibrillary Acidic Protein
View all literature mentionsThis monoclonal targets Neurofilament 160/200 antibody produced in mouse
View all literature mentions